Lucid Drone Technologies Taps T-Mobile to Power Commercial Cleaning Drones
25.4.2022 16:23:00 EEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) announced that Lucid Drone Technologies has chosen the Un-carrier to be the exclusive provider of IoT connectivity and management for their fleet of industrial spraying drones. Together, Lucid Drone Technologies and T-Mobile are collaborating to put maintenance teams and exterior cleaning companies out of harm’s way using drone technology for high-risk facilities maintenance work like exterior soft-wash cleaning and high-rise window washing. The companies also plan to leverage T-Mobile's industry-leading 5G network in the future to fly drones beyond line-of-sight and power more data-intensive capabilities like video streaming.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220424005109/en/
Lucid Drone Technologies has chosen T-Mobile as the exclusive provider of IoT connectivity and management for their growing fleet of industrial spraying drones that provide commercial cleaning services.
A game changer for safety of maintenance teams
Commercial property management firms and developers make significant investments to keep maintenance teams safe. Expensive liability insurance premiums and equipment fees have facilities leaders looking for new and cost-effective solutions. Enter industrial spraying drone pioneer Lucid Drone Technologies and the Un-carrier to deliver a game changer — drones equipped to clean exterior building surfaces and windows.
The next generation of Lucid Drone Technologies industrial spraying drones, powered by T-Mobile for Business, can perform exterior washing for commercial building surfaces and windows, including outdoor stadiums and arenas, hotels, and university structures. That means maintenance teams can steer clear of some high-risk tasks, keeping them safer and focused on other mission critical work.
IoT driving the future of industrial spraying drone technology
T-Mobile’s network powers critical capabilities for Lucid Drone Technologies industrial spraying drones such as real-time sharing of flight data, battery utilization information, hardware diagnostics, and delivery of firmware and software updates. Additionally, T-Mobile Control Center will give Lucid Drone Technologies the ability to view and manage the connectivity of their industrial spraying drones. With the automation and provisioning capabilities of T-Mobile’s IoT platform, Lucid Drone Technologies can easily accelerate deployment of their growing fleet. Lucid Drone Technologies will have near real-time visibility to all their industrial spraying drones with the ability to monitor network conditions and device behavior with T-Mobile Control Center.
Initially, T-Mobile for Business will deliver 4G LTE connectivity to Lucid Drone Technologies industrial spraying drones, providing a reliable connection nationwide. Lucid Drone Technologies expects to utilize the Un-carrier's 5G network in the near future for advanced use cases such as network operations center access, live streaming video and remote piloting. As Americas largest and fastest 5G network, T-Mobile is poised to push IoT to its full potential and catapult adoption — paving the way for new drone applications that rely on low-latency, high-speed data, and real-time location and proximity-based services.
"At Lucid Drone Technologies, we are committed to providing robotic solutions that allow our customers to complete jobs that were once dull, dirty, and dangerous in a safer, faster, and smarter way,” said Andrew Ashur, CEO, Lucid Drone Technologies. “T-Mobile not only allows us to provide our customers with the highest quality of real-time support and connectivity today, but they also have impressive 5G capabilities that allow us to push the frontier limits of responsible robotics."
“Lucid Drone Technologies is a great example of a customer using originality and new technology to solve complicated problems,” said Callie Field, President, T-Mobile Business Group. “It’s not very often that you get to collaborate with these kinds of thinkers, and we’re thrilled to have the opportunity to offer our technology to help bring their vision to life.”
To learn more about Lucid Drone Technologies, visit: www.luciddronetech.com
For more information about IoT from T-Mobile for Business, go to: www.t-mobile.com/business/solutions/iot
Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.
Fastest based on median, overall combined 5G speeds according to analysis by Ookla® of Speedtest Intelligence® data 5G download speeds for Q1 2022. Ookla trademarks used under license and reprinted with permission.
About T-Mobile
T-Mobile U.S. Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile, Metro by T-Mobile and Sprint. For more information please visit: https://www.t-mobile.com.
About Lucid Drone Technologies
Lucid Drone Technologies is a Charlotte, NC-based robotics company that currently designs and builds industrial spraying drones for labor-intensive jobs. Lucid Drone Technologies was started in 2018, and set out to provide a Safer, Faster, and Smarter alternative to traditional dull, dirty, and dangerous jobs.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220424005109/en/
Contact information
Media Contacts
T-Mobile US, Inc. Media Relations
MediaRelations@t-mobile.com
Lucid Drone Technologies
John Dry
jdry@luciddronetech.com
Investor Relations Contact
T-Mobile US, Inc.
investor.relations@t-mobile.com
https://investor.t-mobile.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom